Author

M. Ustav

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1 Assay:proteomics· 1

Frequent Co-Authors

J. B. Case· 2 shared M. S. Diamond· 2 shared S. Miersch· 2 shared A. Ianevski· 1 shared A. Kuznetsov· 1 shared A. Mannik· 1 shared A. Planken· 1 shared A. S. Kim· 1 shared

Activity by Year

2020-2020 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

J. B. Case

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1

A. Kuznetsov, P. Arukuusk, H. Härk, E. Juronen, U. Langel, M. Ustav, J. Järv

The paper studies how a specific ACE2 peptide fragment affects S1-ACE2 complex formation and identifies additional binding sites on the S1 protein.

bioRxiv · Dec 29, 2020 · PreprintBiochemistry

Identification of novel antiviral drug combinations in vitro and tracking their development

A. Ianevski, R. Yao, S. Biza, E. Zusinaite, A. Mannik, G. Kivi, A. Planken, K. Kurg, E.-M. Tombak, M. Ustav, N. Shtaida, E. Kulesskiy, E. Jo, J. Yang, H. Lysvand, , D. E. Kainov

This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.

bioRxiv · Sep 17, 2020 · PreprintMicrobiology

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells

S. Miersch, M. Ustav, Z. Li, J. B. Case, S. Ganaie, G. Matusali, F. Colavita, D. Lapa, M. R. Capobianchi, G. Novelli, J. B. Gupta, S. Jain, P. P. Pandolfi, M. S. Diamond, G. Amarasinghe, , S. S. Sidhu

The paper describes synthetic monoclonal antibodies that neutralize SARS-CoV-2 by binding to the spike protein and blocking ACE2 receptor interaction, showing potent antiviral activity.

bioRxiv · Jun 5, 2020 · PreprintBiochemistry

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

J. B. Case, P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L.-M. Bloyet, Q. Zeng, S. Tahan, L. Droit, M. X. G. Ilagan, M. A. Tartell, G. K. Amarasinghe, J. P. Henderson, S. Miersch, , S. P. J. Whelan

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

bioRxiv · May 18, 2020Microbiology